Drugs / HS-10353
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05195203 | Jan 2021 → Mar 2023 | major depressive disorder | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05937867 | Aug 2023 → Feb 2025 | postpartum depression | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05938179 | Aug 2023 → Nov 2024 | major depressive disorder | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10353 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05195203 ↗ |
| Action | Activate | “positive allosteric modulator of γ-aminobutyric acid A receptors” PMID 42169103 ↗ May 2026 |
| Route | Oral | “Single and multiple oral doses of HS-10353 were safe and well tolerated with a favorable PK profile.” PMID 42169103 ↗ May 2026 |